Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
Crossref DOI link: https://doi.org/10.1186/s12882-021-02242-z
Published Online: 2021-02-02
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gäckler, Anja
Schönermarck, Ulf
Dobronravov, Vladimir
La Manna, Gaetano
Denker, Andrew
Liu, Peng
Vinogradova, Maria
Yoon, Sung-Soo
Praga, Manuel
Text and Data Mining valid from 2021-02-02
Version of Record valid from 2021-02-02
Article History
First Online: 2 February 2021